Interventional Closure of Secundum Type Atrial Septal Defects in Infants Less Than 10 Kilograms: Indications and Procedural Outcome. (13th September 2016)

• Record Type: Journal Article
• Authors: Wyss, Yves; Quandt, Daniel; Weber, Roland; Stiasny, Brian; Weber, Benedikt; Knirsch, Walter; Kretschmar, Oliver
• Is Part Of: Journal of interventional cardiology. Volume 29:Number 6(2016:Dec.)
• Page Start: 646
• Page End: 653
• Publication Date: 2016-09-13
• Subjects: Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.1206
• DOI: 10.1111/joic.12328
• Languages: English
• ISSNs: 0896-4327

Abstract

Abstract : Aims: This study set out to assess indications, feasibility, complications, and clinical outcome of percutaneous transcatheter device closure of atrial septal defects (ASDs) in infants with a bodyweight below 10 kg. Methods and Results: Retrospective single center chart and echocardiography review study from 8/2005–12/2013. Twenty‐eight children with ASD (13 female) with a median age of 1.15 years (0.2–2.8) and a median weight of 7.2 kg (4.5–9.9) were analyzed. Indications for early ASD closure were failure to thrive (n = 15, 54%), bronchopulmonary dysplasia (BPD) with supplemental oxygen dependency (n = 7, 25%), and genetic syndromes with suspected pulmonary hypertension (n = 12, 43%). Device implantation was successful in all patients without any periprocedural mortality or major complication. Clinical outcome after a median follow‐up period of 2.1 years (0.25–7.3) revealed no residual shunt and a significant decrease of right ventricular volume load. Patients with pulmonary hypertension experienced a significant reduction of pulmonary artery/RV pressure. Patients also showed decreased supplemental oxygen dependency and less cardiac medications, but no significant "catch‐up growth" in those with failure to thrive. Conclusion: Interventional ASD closure in children weighing less than 10 kg can be performed without any additional major risks and shows a favorable outcome, especially in selected patients with significant non cardiac co‐morbidities.